Research Article
No access
Published Online: 14 September 2022

COVID-19 and Thyroid Function: A Bi-Directional Two-Sample Mendelian Randomization Study

Publication: Thyroid
Volume 32, Issue Number 9

Abstract

Background: Thyroid dysfunction has been observed among some patients with coronavirus disease (COVID-19). It is unclear whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (or its severity) leads to the development of thyroid dysfunction, or vice versa. In this study, we examined the bi-directional causal relationship between host genetic liability to three COVID-19 phenotypes (including SARS-CoV-2 infection, hospitalized and severe COVID-19) and three thyroid dysfunction traits (including hyperthyroidism, hypothyroidism, and autoimmune thyroid disease [AITD]) and three continuous traits of thyroid hormones (including thyrotropin [TSH] and free thyroxine [fT4] within reference range, and TSH in full range).
Methods: Summary statistics from the largest available meta-analyses of human genome-wide association studies were retrieved for the following variables: SARS-CoV-2 infection (n = 1,348,701), COVID-19 hospitalization (n = 1,557,411), severe COVID-19 (n = 1,059,456), hyperthyroidism (n = 51,823), hypothyroidism (n = 53,423), AITD (n = 755,406), TSH within reference range (n = 54,288), fT4 within reference range (n = 49,269), and TSH in full range (n = 119,715). Using a two-sample Mendelian randomization (MR) approach, the inverse-variance weighted (IVW) method was adopted as the main MR analysis. Weighted median, contamination mixture, MR-Egger, and MR pleiotropy residual sum and outlier (MR-PRESSO) methods were applied as sensitivity analyses.
Results: Host genetic susceptibility to SARS-CoV-2 infection was causally associated with hypothyroidism in the main IVW analysis (per doubling in prevalence of SARS-CoV-2 infection, odds ratio [OR] = 1.335; 95% confidence interval [CI]: 1.167–1.526; p = 2.4 × 10−5, surpassing the Bonferroni multiple-testing threshold). Similar causal estimates were observed in the sensitivity analyses (weighted median: OR = 1.296; CI: 1.066–1.575; p = 9 × 10−3; contamination mixture: OR = 1.356; CI: 1.095–1.818; p = 0.013; MR-Egger: OR = 1.712; CI: 1.202–2.439; p = 2.92 × 10−3, and MR-PRESSO: OR = 1.335; CI: 1.156–1.542; p = 5.73 × 10−4). Host genetic liability to hospitalized or severe COVID-19 was not associated with thyroid dysfunction or thyroid hormone levels. In the reverse direction, there was no evidence to suggest that genetic predisposition to thyroid dysfunction or genetically determined thyroid hormone levels altered the risk of the COVID-19 outcomes.
Conclusions: This bi-directional MR study supports that host response to SARS-CoV-2 viral infection plays a role in the causal association with increased risk of hypothyroidism. Long-term follow-up studies are needed to confirm the expected increased hypothyroidism risk.

Get full access to this article

View all available purchase options and get full access to this article.

References

1. Huang C, Wang Y, Li X, et al. 2020 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506.
2. Hoffmann M, Kleine-Weber H, Schroeder S, et al. 2020 SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271.e8–280.e8.
3. Li MY, Li L, Zhang Y, et al. 2020 Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty 9:45.
4. Scappaticcio L, Pitoia F, Esposito K, et al. 2021 Impact of COVID-19 on the thyroid gland: an update. Rev Endocr Metab Disord 22:803–815.
5. Brancatella A, Ricci D, Cappellani D, et al. 2020 Is subacute thyroiditis an underestimated manifestation of SARS-CoV-2 infection? Insights from a case series. J Clin Endocrinol Metab 105:dgaa537.
6. Ashraf S, Imran MA, Ashraf S, et al. 2021 COVID-19: a potential trigger for thyroid dysfunction. Am J Med Sci 362:303–307.
7. Feghali K, Atallah J, Norman C 2021 Manifestations of thyroid disease post COVID-19 illness: report of Hashimoto thyroiditis, Graves' disease, and subacute thyroiditis. J Clin Transl Endocrinol Case Rep 22:100094.
8. Muller I, Cannavaro D, Dazzi D, et al. 2020 SARS-CoV-2-related atypical thyroiditis. Lancet Diabetes Endocrinol 8:739–741.
9. Shrestha RT, Hennessey J 2015 Acute and subacute, and Riedel's thyroiditis. In: Feingold KR, Anawalt B, Boyce A, et al. (eds) Endotext. MDText.com, Inc., South Dartmouth, MA, p 2000. Available at https://www.ncbi.nlm.nih.gov/books/NBK285553 (accessed April 17, 2022).
10. Fatourechi V, Aniszewski JP, Fatourechi GZ, et al. 2003 Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab 88:2100–2105.
11. Nakano Y, Kurihara H, Sasaki J 2011 Graves' disease following subacute thyroiditis. Tohoku J Exp Med 225:301–309.
12. Papi G, Ezzat S 2004 Progression of subacute (de Quervain's) thyroiditis into Hashimoto's thyroiditis. Thyroid 14:477–478.
13. Mateu-Salat M, Urgell E, Chico A 2020 SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves' disease after COVID-19. J Endocrinol Invest 43:1527–1528.
14. Lui DTW, Lee CH, Chow WS, et al. 2021 Insights from a prospective follow-up of thyroid function and autoimmunity among COVID-19 survivors. Endocrinol Metab (Seoul) 36:582–589.
15. Lui DTW, Lee CH, Chow WS, et al. 2021 Thyroid dysfunction in relation to immune profile, disease status, and outcome in 191 patients with COVID-19. J Clin Endocrinol Metab 106:e926–e935.
16. Knack RS, Hanada T, Knack RS, et al. 2021 Hashimoto's thyroiditis following SARS-CoV-2 infection. BMJ Case Rep 14:e244909.
17. Lania A, Sandri MT, Cellini M, et al. 2020 Thyrotoxicosis in patients with COVID-19: the THYRCOV study. Eur J Endocrinol 183:381–387.
18. Pizzocaro A, Colombo P, Vena W, et al. 2021 Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study. Endocrine 73:255–260.
19. Khoo B, Tan T, Clarke SA, et al. 2021 Thyroid function before, during, and after COVID-19. J Clin Endocrinol Metab 106:e803–e811.
20. Damara FA, Muchamad GR, Ikhsani R, et al. 2021 Thyroid disease and hypothyroidism are associated with poor COVID-19 outcomes: a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr 15:102312.
21. Brix TH, Hegedus L, Hallas J, et al. 2021 Risk and course of SARS-CoV-2 infection in patients treated for hypothyroidism and hyperthyroidism. Lancet Diabetes Endocrinol 9:197–199.
22. van Gerwen M, Alsen M, Little C, et al. 2020 Outcomes of patients with hypothyroidism and COVID-19: a retrospective cohort study. Front Endocrinol (Lausanne) 11:565.
23. Bogojevic M, Bansal V, Pattan V, et al. 2022 Association of hypothyroidism with outcomes in hospitalized adults with COVID-19: results from the International SCCM Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry. Clin Endocrinol (Oxf). [Epub ahead of print];.
24. Davies NM, Holmes MV, Davey Smith G 2018 Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 362:k601.
25. Burgess S, Butterworth A, Thompson SG 2013 Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol 37:658–665.
26. Bowden J, Davey Smith G, Haycock PC, et al. 2016 Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol 40:304–314.
27. Bowden J, Davey Smith G, Burgess S2015 Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 44:512–525.
28. Burgess S, Foley CN, Allara E, et al. 2020 A robust and efficient method for Mendelian randomization with hundreds of genetic variants. Nat Commun 11:376.
29. Verbanck M, Chen CY, Neale B, et al. 2018 Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet 50:693–698.
30. Garmendia Madariaga A, Santos Palacios S, Guillen-Grima F, et al. 2014 The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab 99:923–931.
31. Teumer A, Chaker L, Groeneweg S, et al. 2018 Genome-wide analyses identify a role for SLC17A4 and AADAT in thyroid hormone regulation. Nat Commun 9:4455.
32. Abel KM, Carr MJ, Ashcroft DM, et al. 2021 Association of SARS-CoV-2 infection with psychological distress, psychotropic prescribing, fatigue, and sleep problems among UK primary care patients. JAMA Netw Open 4:e2134803.
33. Becker JH, Lin JJ, Doernberg M, et al. 2021 Assessment of cognitive function in patients after COVID-19 infection. JAMA Netw Open 4:e2130645.
34. Taquet M, Geddes JR, Husain M, et al. 2021 6-Month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 8:416–427.
35. Pasqualetti G, Pagano G, Rengo G, et al. 2015 Subclinical hypothyroidism and cognitive impairment: systematic review and meta-analysis. J Clin Endocrinol Metab 100:4240–4248.
36. Bode H, Ivens B, Bschor T, et al. 2021 Association of hypothyroidism and clinical depression: a systematic review and meta-analysis. JAMA Psychiatry 78:1375–1383.
37. Loh HH, Lim LL, Yee A, et al. 2019 Association between subclinical hypothyroidism and depression: an updated systematic review and meta-analysis. BMC Psychiatry 19:12.
38. Saevarsdottir S, Olafsdottir TA, Ivarsdottir EV, et al. 2020 FLT3 stop mutation increases FLT3 ligand level and risk of autoimmune thyroid disease. Nature 584:619–623.
39. Covid-19 Host Genetics Initiative 2021 Mapping the human genetic architecture of COVID-19. Nature 600:472–477.
40. Boelaert K, Visser WE, Taylor PN, et al. 2020 Endocrinology in the time of COVID-19: management of hyperthyroidism and hypothyroidism. Eur J Endocrinol 183:G33–G39.
41. Burgess S, Davies NM, Thompson SG 2016 Bias due to participant overlap in two-sample Mendelian randomization. Genet Epidemiol 40:597–608.
42. Zhou W, Brumpton B, Kabil O, et al. 2020 GWAS of thyroid stimulating hormone highlights pleiotropic effects and inverse association with thyroid cancer. Nat Commun 11:3981.

Information & Authors

Information

Published In

cover image Thyroid®
Thyroid
Volume 32Issue Number 9September 2022
Pages: 1037 - 1050
PubMed: 35734897

History

Published online: 14 September 2022
Published in print: September 2022
Published ahead of print: 19 July 2022
Published ahead of production: 23 June 2022

Permissions

Request permissions for this article.

Topics

    Authors

    Affiliations

    Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hung Hom, Hong Kong.
    Ching-Man Tang
    Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hung Hom, Hong Kong.
    Ching-Lung Cheung [email protected]
    Department of Pharmacology and Pharmacy, The University of Hong Kong, Pokfulam, Hong Kong.

    Notes

    Address correspondence to: Ching-Lung Cheung, PhD, Department of Pharmacology and Pharmacy, The University of Hong Kong, Pokfulam, Hong Kong [email protected]

    Authors' Contributions

    G.H.-Y.L. and C.-L.C. conceptualized and designed the study. G.H.-Y.L. and C.-M.T. conducted the statistical analysis. G.H.-Y.L. drafted the article. All authors were involved in interpreting the data and revising the article for final submission.

    Author Disclosure Statement

    The authors have nothing to disclose.

    Funding Information

    The work was supported by the Start-up Fund for Research Assistant Professors under the Strategic Hiring Scheme of The Hong Kong Polytechnic University, granted to G.H.-Y.L. (P0036047).

    Metrics & Citations

    Metrics

    Citations

    Export citation

    Select the format you want to export the citations of this publication.

    View Options

    Get Access

    Access content

    To read the fulltext, please use one of the options below to sign in or purchase access.

    Society Access

    If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

    Restore your content access

    Enter your email address to restore your content access:

    Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

    View options

    PDF/EPUB

    View PDF/ePub

    Full Text

    View Full Text

    Media

    Figures

    Other

    Tables

    Share

    Share

    Copy the content Link

    Share on social media

    Back to Top